INTARCIA PRESS RELEASES
June 6, 2007	FierceBiotech Names Intarcia Therapeutics as One of the “Fierce 15" Biotech Companies of 2007
May 21, 2007	Intarcia Therapeutics Announces Presentation of Final Results from a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
April 12, 2007	Intarcia Therapeutics Announces Final Results From A Phase 2 Study Of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
March 19, 2007	Intarcia Raises $50 Million in a Series BB Financing
Nov 15, 2005	Intarcia Announces Interim Results from Phase 2 Study of Omega Interferon in HCV

MEDIA ARCHIVE

INTARCIA PRESS RELEASES